Literature DB >> 17349525

Growth rates of renal cell carcinoma and oncocytoma under surveillance are similar.

Wendy Siu1, Khaled S Hafez, William K Johnston, J Stuart Wolf.   

Abstract

OBJECTIVE: Through examining our experience with renal mass surveillance, we hoped to determine factors suggestive of renal cell carcinoma.
METHODS: We followed for at least 1 year 41 patients with 47 solid renal masses (mean diameter 2.0 cm, range 0.8-5). Mean surveillance duration was 29 months and was more than 2 years for 23 masses (49%).
RESULTS: Overall mean increase in diameter was 0.27 cm/year, but 21 (45%) did not grow, and mean growth rate was 0.5 cm/year in the 26 that did grow. Of the masses, 14 have been treated, 33 continue to be followed, and pathology is known in 16 (34%). Growth was seen in all 6 known oncocytomas (mean 0.52 cm/year), 80% of the 10 biopsy proven renal cell carcinomas grew (mean 0.71 cm/year), but only 12 (39%) of the masses with unknown pathology (0.08 cm/year). There was no factor that distinguished oncocytomas from renal cell carcinomas. In 1 patient, a 3-cm mass that had not changed in size for 6 years doubled in size over 6 months, and metastatic disease developed.
CONCLUSIONS: Although growth of most renal masses is slow, some grow quickly, and delayed growth with metastases can occur. No factor distinguished renal cell carcinomas from oncocytomas. Surveillance for renal masses remains an option but must be rigorous and continuous, and is not without risk of progression.

Entities:  

Mesh:

Year:  2007        PMID: 17349525     DOI: 10.1016/j.urolonc.2006.07.018

Source DB:  PubMed          Journal:  Urol Oncol        ISSN: 1078-1439            Impact factor:   3.498


  21 in total

Review 1.  Contemporary Status of Percutaneous Ablation for the Small Renal Mass.

Authors:  Benjamin J Shin; Jeffrey Forris Beecham Chick; S William Stavropoulos
Journal:  Curr Urol Rep       Date:  2016-03       Impact factor: 3.092

2.  Molecular characterization of kidney cancer: association of hyaluronic acid family with histological subtypes and metastasis.

Authors:  Andrew Chi; Samir P Shirodkar; Diogo O Escudero; Obi O Ekwenna; Travis J Yates; Rajinikanth Ayyathurai; Michael Garcia-Roig; Jeffrey C Gahan; Murugesan Manoharan; Vincent G Bird; Vinata B Lokeshwar
Journal:  Cancer       Date:  2011-09-01       Impact factor: 6.860

Review 3.  Imaging features of solid renal masses.

Authors:  Massimo Galia; Domenico Albano; Alberto Bruno; Antonino Agrusa; Giorgio Romano; Giuseppe Di Buono; Francesco Agnello; Giuseppe Salvaggio; Ludovico La Grutta; Massimo Midiri; Roberto Lagalla
Journal:  Br J Radiol       Date:  2017-07-13       Impact factor: 3.039

4.  Role of MRI in indeterminate renal mass: diagnostic accuracy and impact on clinical decision making.

Authors:  Taekmin Kwon; In Gab Jeong; Sangjun Yoo; JungBok Lee; Sungwoo Hong; Dalsan You; Jun Hyuk Hong; Hanjong Ahn; Choung-Soo Kim
Journal:  Int Urol Nephrol       Date:  2015-02-14       Impact factor: 2.370

Review 5.  Small renal masses progressing to metastases under active surveillance: a systematic review and pooled analysis.

Authors:  Marc C Smaldone; Alexander Kutikov; Brian L Egleston; Daniel J Canter; Rosalia Viterbo; David Y T Chen; Michael A Jewett; Richard E Greenberg; Robert G Uzzo
Journal:  Cancer       Date:  2011-07-15       Impact factor: 6.860

6.  Growth pattern of renal cell carcinoma (RCC) in patients with delayed surgical intervention.

Authors:  Xue-Song Li; Lin Yao; Kan Gong; Wei Yu; Qun He; Li-Qun Zhou; Zhi-Song He
Journal:  J Cancer Res Clin Oncol       Date:  2011-11-22       Impact factor: 4.553

7.  Growth rates and outcomes of observed large renal masses.

Authors:  Naji J Touma; Gregory W Hosier; Michael A Di Lena; Robert J Leslie; Louisa Ho; Alexandre Menard; D Robert Siemens
Journal:  Can Urol Assoc J       Date:  2018-12-03       Impact factor: 1.862

8.  Natural history, growth kinetics, and outcomes of untreated clinically localized renal tumors under active surveillance.

Authors:  Paul L Crispen; Rosalia Viterbo; Stephen A Boorjian; Richard E Greenberg; David Y T Chen; Robert G Uzzo
Journal:  Cancer       Date:  2009-07-01       Impact factor: 6.860

9.  Charlson score as a single pertinent criterion to select candidates for active surveillance among patients with small renal masses.

Authors:  François Audenet; Marie Audouin; Sarah J Drouin; Eva Comperat; Pierre Mozer; Emmanuel Chartier-Kastler; Arnaud Méjean; Olivier Cussenot; Shahrokh F Shariat; Morgan Rouprêt
Journal:  World J Urol       Date:  2013-07-20       Impact factor: 4.226

Review 10.  Kidney cancer ablative therapy: indications and patient selection.

Authors:  Daniel S Lehman; Jaime Landman
Journal:  Curr Urol Rep       Date:  2008-01       Impact factor: 3.092

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.